Search This Blog

Monday, September 28, 2020

FDA places partial hold on Inovio's pivotal COVID-19 vaccine study

The FDA has placed a partial clinical hold on Inovio Pharmaceuticals' (NASDAQ:INO) Phase 2/3 clinical trial of COVID-19 vaccine candidate INO-4800 and the Cellectra 2000 delivery device.

The agency cites the need to address additional questions about the study. The company says it plans to submit its response next month.

A partial clinical hold suspends enrollment but allows current participants to continue treatment.

The company's Phase 1 trial is not affected.

https://seekingalpha.com/news/3617568-fda-places-partial-hold-on-inovios-pivotal-covidminus-19-vaccine-study

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.